Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.


BACKGROUND Recent preclinical and clinical studies indicate beneficial effects from combining radiotherapy with either anti-angiogenic drugs or anti-epidermal growth factor receptor (EGFR)-targeting agent. To investigate the effect of combining these approaches, we evaluated in vivo the antitumor efficacy of the anti-angiogenic compound sunitinib, an oral… (More)
DOI: 10.1093/annonc/mdp070